Analysts' ratings for Corteva CTVA over the last quarter vary from bullish to bearish, as provided by 14 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 8 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 2 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 1 | 0 | 0 |
| 3M Ago | 2 | 4 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $78.71, a high estimate of $92.00, and a low estimate of $70.00. This upward trend is apparent, with the current average reflecting a 8.36% increase from the previous average price target of $72.64.
Analyzing Analyst Ratings: A Detailed Breakdown
In examining recent analyst actions, we gain insights into how financial experts perceive Corteva. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Arun Viswanathan | RBC Capital | Raises | Outperform | $85.00 | $74.00 |
| Joshua Spector | UBS | Raises | Buy | $90.00 | $76.00 |
| Joel Jackson | BMO Capital | Raises | Outperform | $86.00 | $74.00 |
| Benjamin Theurer | Barclays | Raises | Equal-Weight | $75.00 | $70.00 |
| Richard Garchitorena | Wells Fargo | Raises | Overweight | $82.00 | $79.00 |
| Laurence Alexander | Jefferies | Raises | Buy | $92.00 | $80.00 |
| Benjamin Theurer | Barclays | Raises | Equal-Weight | $70.00 | $64.00 |
| Richard Garchitorena | Wells Fargo | Raises | Overweight | $79.00 | $73.00 |
| Kristen Owen | Oppenheimer | Raises | Outperform | $75.00 | $72.00 |
| Vincent Andrews | Morgan Stanley | Raises | Overweight | $71.00 | $65.00 |
| Patrick Cunningham | Citigroup | Raises | Buy | $78.00 | $75.00 |
| Aleksey Yefremov | Keybanc | Raises | Overweight | $72.00 | $71.00 |
| Joshua Spector | UBS | Raises | Buy | $76.00 | $74.00 |
| Bradley Thomas | Keybanc | Raises | Overweight | $71.00 | $70.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corteva compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Corteva's stock. This comparison reveals trends in analysts' expectations over time.
Capture valuable insights into Corteva's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Corteva analyst ratings.
Unveiling the Story Behind Corteva
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
Corteva: Financial Performance Dissected
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Corteva's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -1.67% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Corteva's net margin excels beyond industry benchmarks, reaching 14.76%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.71%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.57%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.17.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
